Copper Modulation as a Therapy for Alzheimer's Disease?
Figure 1
Assessment of Aβ burden in APP/PS1 mice by Western blot. Total hemisphere homogenates (sonicated in PBS followed by centrifugation at 100,000×g for 30 minutes at 4˚C and subsequent isolation of the soluble and insoluble fractions. The insoluble fraction was resuspended in PBS prior to a BCA assay and subsequent Western blot) were assessed for Aβ content using both an in-house antibody (WO2) (a) and a commercial (4G8) (b) antibody. A significant reduction in insoluble Aβ was seen with both antibodies for the combined high copper and cholesterol treatment group only, as compared to the Tg control group (Tg).
